Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H9N2 (6-2) AA ca Reassortant
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
H9N2 (6-2) AA ca Reassortant is a live attenuated influenza vaccine candidate developed using a reassorted avian influenza virus backbone. The "6-2" designation refers to the genetic composition of the virus, with six internal genes derived from an A/Ann Arbor/6/60 cold-adapted (ca) master donor strain and two surface glycoprotein genes—hemagglutinin (HA) and neuraminidase (NA)—from an avian-origin H9N2 virus. This reassortant is designed to induce immunity against potential pandemic strains of avian influenza by presenting novel HA and NA antigens while maintaining attenuation and safety through the internal gene constellation. The vaccine has demonstrated good tolerability and immunogenicity in seronegative individuals but shows restricted replication in humans due to its attenuated nature[1]. It is primarily intended for pandemic preparedness against emerging zoonotic avian influenza viruses.
- Other names
- live attenuated H9N2 influenza vaccineH9N2 G9/AA ca vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on H9N2 (6-2) AA ca Reassortant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on H9N2 (6-2) AA ca Reassortant.